Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 7, 2008

Takeda Pays Alnylam $20M upon Technology Transfer

  • Alnylam Pharmaceuticals achieved a $20 million technology transfer milestone from Takeda Pharmaceutical Company (as per the agreement formed between the companies in May 2008). This payment is related to the transfer of Alnylam's platform technology including documents, materials, and know-how to Takeda for the development of RNAi therapeutics.

    Alnylam received an initial payment of $100 million and stands to earn another $30 million as a technology transfer milestone fee in the near term. The strategic alliance formed between the firms is valued at over $1 billion in milestones related to R&D and commercialization.

    Besides gaining access to Alnylam’s RNAi technology platform for immediate use in oncology and metabolic disorders, Takeda also became the company’s Asian partner for RNAi therapeutics for the next five years.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »